Noradrenalin Léčiva (Noradrenaline Tartrate)

The drug acts as a direct agonist at alpha‑1 and beta‑1 adrenergic receptors. Alpha‑1 stimulation causes vasoconstriction, while beta‑1 activation increases heart contractility and rate, together elevating systemic vascular resistance and cardiac output to improve arterial pressure.

Dosing is individualized and must be determined by the prescribing clinician. The infusion rate is titrated to the patient’s hemodynamic response, aiming for a target mean arterial pressure while monitoring for adverse effects.

Safety data in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under specialist supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Both agents raise blood pressure, but noradrenaline primarily stimulates alpha‑1 receptors, giving strong vasoconstriction with modest beta‑1 activity, whereas dopamine has dose‑dependent effects on dopaminergic, beta‑1 and alpha‑1 receptors. Noradrenaline is generally preferred for septic shock because it provides more predictable vasoconstriction with fewer tachyarrhythmias.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

It is given as a continuous intravenous infusion. The solution is added to a compatible carrier fluid and delivered via a calibrated infusion pump, with the rate adjusted according to the patient’s blood pressure and clinical response.

Serious concerns include severe hypertension, myocardial ischemia, tissue necrosis from extravasation, and life‑threatening arrhythmias. Continuous hemodynamic monitoring and careful site inspection are essential to detect these complications early.

Patients with known hypersensitivity to noradrenaline or any excipients, those with uncontrolled ventricular tachyarrhythmias, or individuals in whom excessive vasoconstriction could worsen peripheral ischemia should not receive the drug.